Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Edahiro, Yoko; Ochiai, Tomonori; Hashimoto, Yoshinori; Morishita, Soji; Shirane, Shuichi; Inano, Tadaaki; Furuya, Chiho; Koike, Michiaki; Noguchi, Masaaki; Usuki, Kensuke; Shiratsuchi, Motoaki; Nakajima, Kei; Ohtsuka, Eiichi; Tanaka, Hiroaki; Kawata, Eri; Nakamae, Mika; Ueda, Yasunori; Aota, Yasuo; Sugita, Yoshiaki; Ohara, Shuichi; Yamasaki, Satoshi; Asagoe, Kohsuke; Yoshida, Shuro; Yamanouchi, Jun; Suzuki, Shinya; Kondo, Toshinori; Kanisawa, Yuji; Toyama, Kohtaro; Omura, Hiromi; Mizuchi, Daisuke; Sakamaki, Sumio; Komatsu, Norio

doi:10.1007/s12185-023-03592-0

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies of MDS/MPN-RS-T were based on the 2008 or 2016 revision of the WHO classification and were restricted to people with ≥15% bone marrow RS [ 8 – 12 , 20 ]. We aimed to describe the clinical and molecular landscapes of MDS/MPN- SF3B1 -T patients, compare the prognoses of people with < or ≥15% bone marrow RS, and develop prognostic models.…”

Section: Introductionmentioning

confidence: 99%

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Li,

Qin,

et al. 2024

Leukemia

View full text Add to dashboard Cite

We investigated data from 180 consecutive patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) who were diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid neoplasms to identify covariates associated with survival. At a median follow-up of 48 months (95% confidence interval [CI] 35–61 months), the median survival was 69 months (95% CI 59–79 months). Patients with bone marrow ring sideroblasts (RS) < 15% had shorter median overall survival (OS) than did those with bone marrow RS ≥ 15% (41 months [95% CI 32–50 months] versus 76 months [95% CI 59–93 months]; P < 0.001). According to the univariable analyses of OS, age ≥ 65 years (P < 0.001), hemoglobin concentration (Hb) < 80 g/L (P = 0.090), platelet count (PLT) ≥ 800 × 10E + 9/L (P = 0.087), bone marrow RS < 15% (P < 0.001), the Revised International Prognostic Scoring System (IPSS-R) cytogenetic category intermediate/poor/very poor (P = 0.005), SETBP1 mutation (P = 0.061) and SRSF2 mutation (P < 0.001) were associated with poor survival. Based on variables selected from univariable analyses, two separate survival prediction models, a clinical survival model, and a clinical-molecular survival model, were developed using multivariable analyses with the minimum value of the Akaike information criterion (AIC) to specifically predict outcomes in patients with MDS/MPN-SF3B1-T according to the 2022 WHO classification.

show abstract

Section: Introductionmentioning

confidence: 99%

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Li,

Qin,

et al. 2024

Leukemia

View full text Add to dashboard Cite

show abstract

Predicting survival in myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Xiao,

Li,

Qin

et al. 2024

Preprint

View full text Add to dashboard Cite

We interrogated data from 180 consecutive subjects with myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid neoplasms to identify co-variates associated with survival. At a median follow-up of 45 months (Inter-Quartile Range [IQR], 19–73 months), median survival was 70 months (95% Confidence Interval [CI], 57, 84 months). Subjects with bone marrow ring sideroblasts < 15% had briefer median survival compared with those in whom it was ≥ 15% (41 months [32, 50 months] versus 80 months [63, 97 months]; P = 0.003). In multi-variable analyses, age ≥ 65 years (P = 0.005), haemoglobin concentration < 80 g/L (P = 0.008), platelet concentration ≥ 800×10E + 9/L (P = 0.02), bone marrow ring sideroblasts < 15% (P = 0.007), complex cytogenetics (P = 0.04) and SETBP1 mutation (P = 0.004) were independently associated with worse survival. Using these data we divided subjects into 3 risk cohorts: (1) low- (N = 77; median 96 months [72, 120 months]); (2) intermediate- (N = 70; median 56 months [32, 80 months]); and (3) high-risk (N = 7; median 17 months [15, 19 months]; All pairwise comparisons P < 0.0001). Our model, if validated, should help physicians estimate survival in persons with MDS/MPN-SF3B1-T in the 2022 WHO classification.

show abstract

Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Cited by 2 publications

References 19 publications

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Predicting survival in myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Contact Info

Product

Resources

About